Odprti razpisi › Horizon Europe

Odprt

Development of monoclonal antibodies to prevent and treat infections from Flaviviruses

Horizon Europe · Cluster 1 – Health · HORIZON-HLTH-2027-01-DISEASE-06

Funding to advance monoclonal antibodies against selected flaviviruses, such as dengue or Zika, up to first clinical trials.

Presodi za moj projektPomoč pri tem razpisu

O čem je ta razpis?

The topic funds research and innovation projects that advance existing monoclonal antibody candidates against selected flaviviruses from preclinical tests to first-in-human safety studies.

Kaj ta razpis financira?

Scope

The topic funds the further development of existing prophylactic and therapeutic monoclonal antibody candidates against selected flaviviruses, in support of the European Medical Countermeasures Strategy. Each proposal should explicitly state which one of the following viruses it targets, and the work should address only that virus:

  • Dengue virus;
  • tick-borne encephalitis virus;
  • Japanese encephalitis virus;
  • West Nile fever virus;
  • yellow fever virus;
  • Zika virus.

Proposals should focus on antibodies produced or derived from a single cell clone through recombinant expression, such as B-cell derived antibodies, hybridoma derived antibodies and nanobodies.

Research areas

Proposals should address all of the following:

  • where necessary, completing in-vitro characterisation of the candidates (target specificity, epitope and ability to impair viral functions);
  • in-vivo tests in at least one animal model, or in humanised immune system animal models where available, and in non-human primates if regulators require it;
  • evaluation of antibody-dependent enhancement risk where scientifically relevant;
  • production of GMP batches of the most promising candidates;
  • first-in-human clinical safety studies with a clear regulatory pathway to market authorisation.

Attention should be paid to sex, age, ethnicity and disability. Projects should engage with regulators in good time and use existing research infrastructures, such as those that contributed to ISIDORe services.

Expected outcomes

Better understanding of and access to experimental monoclonal antibodies for emerging and re-emerging viral infections, and candidate antibody therapies available for clinical use in an epidemic or pandemic.

Ključni podatki o razpisu na kratko

Proračun teme
37.300.000 €
Najnižji znesek na projekt
9.000.000 €
Najvišji znesek na projekt
10.000.000 €
Oznaka razpisa
HORIZON-HLTH-2027-01-DISEASE-06
Program
Horizon Europe
Funder
European Union, Horizon Europe
Expected number of projects
4

Kdo se lahko prijavi na ta razpis?

  • Participation of third countries where the targeted viruses are endemic or where outbreaks have occurred or are ongoing is encouraged.
  • The participation of start-ups, micro, small and medium-sized enterprises is encouraged.
  • Applicants should describe their clinical studies in the dedicated annex using the template in the submission system.

Preverite upravičenost in kako se vaš projekt ujema z razpisom

V brezplačnem računu za vašo organizacijo preverimo pogoje upravičenosti v razpisni dokumentaciji in ocenimo, kako dobro se vaš projekt ujema s tem razpisom.

Ustvarite brezplačen račun in preverite upravičenost

Kdaj je rok za oddajo?

17. februarja 2027 (103 dni)

13 April 2027 (single-stage call).

Vas razpis zanima? Povzetek je pripravila umetna inteligenca iz uradne razpisne dokumentacije. Podrobnosti se lahko razlikujejo, zato pred prijavo preverite uradno stran razpisa. Pred odločitvijo preberite uradno razpisno dokumentacijo. Zavezujoče je vedno uradno besedilo.

Uradna stran razpisa ↗

Vir: portal EU Funding & Tenders in uradna razpisna dokumentacija. Uradna stran razpisa Zadnja posodobitev: 6. oktobra 2026.